These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9154964)

  • 1. Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.
    Dal Piaz V; Giovannoni MP; Castellana C; Palacios JM; Beleta J; Doménech T; Segarra V
    J Med Chem; 1997 May; 40(10):1417-21. PubMed ID: 9154964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
    Duplantier AJ; Biggers MS; Chambers RJ; Cheng JB; Cooper K; Damon DB; Eggler JF; Kraus KG; Marfat A; Masamune H; Pillar JS; Shirley JT; Umland JP; Watson JW
    J Med Chem; 1996 Jan; 39(1):120-5. PubMed ID: 8568798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.
    Barnette MS; Manning CD; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
    J Pharmacol Exp Ther; 1995 May; 273(2):674-9. PubMed ID: 7752069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site.
    Barnette MS; Grous M; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1396-402. PubMed ID: 7791113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
    Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH
    J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDP840: a novel inhibitor of PDE-4.
    Perry MJ; O'Connell J; Walker C; Crabbe T; Baldock D; Russell A; Lumb S; Huang Z; Howat D; Allen R; Merriman M; Walls J; Daniel T; Hughes B; Laliberte F; Higgs GA; Owens RJ
    Cell Biochem Biophys; 1998; 29(1-2):113-32. PubMed ID: 9631241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.
    Collado MC; Beleta J; Martinez E; Miralpeix M; Domènech T; Palacios JM; Hernández J
    Br J Pharmacol; 1998 Mar; 123(6):1047-54. PubMed ID: 9559885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.
    Crespo MI; Pagès L; Vega A; Segarra V; López M; Doménech T; Miralpeix M; Beleta J; Ryder H; Palacios JM
    J Med Chem; 1998 Oct; 41(21):4021-35. PubMed ID: 9767640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of phosphodiesterase IV and intracellular calcium levels in human polymorphonuclear leukocytes.
    Villagrasa V; Navarrete C; Sanz C; Berto L; Perpiñá M; Cortijo J; Morcillo EJ
    Methods Find Exp Clin Pharmacol; 1996 May; 18(4):239-45. PubMed ID: 8803956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
    Jacobitz S; McLaughlin MM; Livi GP; Burman M; Torphy TJ
    Mol Pharmacol; 1996 Oct; 50(4):891-9. PubMed ID: 8863835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.
    Iwasaki T; Kondo K; Kuroda T; Moritani Y; Yamagata S; Sugiura M; Kikkawa H; Kaminuma O; Ikezawa K
    J Med Chem; 1996 Jul; 39(14):2696-704. PubMed ID: 8709099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction.
    Giovannoni MP; Vergelli C; Biancalani C; Cesari N; Graziano A; Biagini P; Gracia J; Gavaldà A; Dal Piaz V
    J Med Chem; 2006 Aug; 49(17):5363-71. PubMed ID: 16913726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.
    Ukita T; Sugahara M; Terakawa Y; Kuroda T; Wada K; Nakata A; Ohmachi Y; Kikkawa H; Ikezawa K; Naito K
    J Med Chem; 1999 Mar; 42(6):1088-99. PubMed ID: 10090791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions.
    Lugnier C; Muller B; Le Bec A; Beaudry C; Rousseau E
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1142-51. PubMed ID: 8389853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential use of selective phosphodiesterase inhibitors in the treatment of asthma.
    Murray KJ; Eden RJ; England PJ; Dolan J; Grimsditch DC; Stutchbury CA; Patel B; Reeves ML; Worby A; Torphy TJ
    Agents Actions Suppl; 1991; 34():27-46. PubMed ID: 1665307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors.
    Giovannoni MP; Cesari N; Graziano A; Vergelli C; Biancalani C; Biagini P; Dal Piaz V
    J Enzyme Inhib Med Chem; 2007 Jun; 22(3):309-18. PubMed ID: 17674813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus.
    Cortijo J; Bou J; Beleta J; Cardelús I; Llenas J; Morcillo E; Gristwood RW
    Br J Pharmacol; 1993 Feb; 108(2):562-8. PubMed ID: 8383567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
    Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
    Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
    Kelly JJ; Barnes PJ; Giembycz MA
    Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of human type 4 phosphodiesterase isostates by (R, R)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3- methyl-1-pyrrolidinecarboxylate.
    Tian G; Rocque WJ; Wiseman JS; Thompson IZ; Holmes WD; Domanico PL; Stafford JA; Feldman PL; Luther MA
    Biochemistry; 1998 May; 37(19):6894-904. PubMed ID: 9578576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.